These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 37974964)
1. Discovery of carboxyl-containing heteroaryldihydropyrimidine derivatives as novel HBV capsid assembly modulators with significantly improved metabolic stability. Zhao S; Wang Y; Zhang X; Qiao L; Wang S; Jin Y; Wu S; Li Y; Zhan P; Liu X RSC Med Chem; 2023 Nov; 14(11):2380-2400. PubMed ID: 37974964 [TBL] [Abstract][Full Text] [Related]
2. Discovery of hepatitis B virus capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate (GLS4). Ren Q; Liu X; Luo Z; Li J; Wang C; Goldmann S; Zhang J; Zhang Y Bioorg Med Chem; 2017 Feb; 25(3):1042-1056. PubMed ID: 28082068 [TBL] [Abstract][Full Text] [Related]
3. Design, Synthesis, and Biological Evaluation of Novel Thioureidobenzamide (TBA) Derivatives as HBV Capsid Assembly Modulators. Wang M; Zhang J; Dou Y; Liang M; Xie Y; Xue P; Liu L; Li C; Wang Y; Tao F; Zhang X; Hu H; Feng K; Zhang L; Wu Z; Chen Y; Zhan P; Jia H J Med Chem; 2023 Oct; 66(20):13968-13990. PubMed ID: 37839070 [TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and evaluation of heteroaryldihydropyrimidine analogues bearing spiro ring as hepatitis B virus capsid protein inhibitors. Ma Y; Zhao S; Ren Y; Cherukupalli S; Li Q; Woodson ME; Bradley DP; Tavis JE; Liu X; Zhan P Eur J Med Chem; 2021 Dec; 225():113780. PubMed ID: 34438123 [TBL] [Abstract][Full Text] [Related]
5. Discovery and Mechanistic Study of Benzamide Derivatives That Modulate Hepatitis B Virus Capsid Assembly. Wu S; Zhao Q; Zhang P; Kulp J; Hu L; Hwang N; Zhang J; Block TM; Xu X; Du Y; Chang J; Guo JT J Virol; 2017 Aug; 91(16):. PubMed ID: 28566379 [TBL] [Abstract][Full Text] [Related]
6. 3-((R)-4-(((R)-6-(2-Bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholin-2-yl)propanoic Acid (HEC72702), a Novel Hepatitis B Virus Capsid Inhibitor Based on Clinical Candidate GLS4. Ren Q; Liu X; Yan G; Nie B; Zou Z; Li J; Chen Y; Wei Y; Huang J; Luo Z; Gu B; Goldmann S; Zhang J; Zhang Y J Med Chem; 2018 Feb; 61(3):1355-1374. PubMed ID: 29381358 [TBL] [Abstract][Full Text] [Related]
7. A New Role for Capsid Assembly Modulators To Target Mature Hepatitis B Virus Capsids and Prevent Virus Infection. Ko C; Bester R; Zhou X; Xu Z; Blossey C; Sacherl J; Vondran FWR; Gao L; Protzer U Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31658963 [TBL] [Abstract][Full Text] [Related]
8. In vitro inhibition of HBV replication by a novel compound, GLS4, and its efficacy against adefovir-dipivoxil-resistant HBV mutations. Wang XY; Wei ZM; Wu GY; Wang JH; Zhang YJ; Li J; Zhang HH; Xie XW; Wang X; Wang ZH; Wei L; Wang Y; Chen HS Antivir Ther; 2012; 17(5):793-803. PubMed ID: 22668794 [TBL] [Abstract][Full Text] [Related]
9. Antiviral Activity and Pharmacokinetics of the Hepatitis B Virus (HBV) Capsid Assembly Modulator GLS4 in Patients With Chronic HBV Infection. Zhang H; Wang F; Zhu X; Chen Y; Chen H; Li X; Wu M; Li C; Liu J; Zhang Y; Ding Y; Niu J Clin Infect Dis; 2021 Jul; 73(2):175-182. PubMed ID: 32649736 [TBL] [Abstract][Full Text] [Related]
10. Design and Synthesis of Hepatitis B Virus (HBV) Capsid Assembly Modulators and Evaluation of Their Activity in Mammalian Cell Model. Spunde K; Vigante B; Dubova UN; Sipola A; Timofejeva I; Zajakina A; Jansons J; Plotniece A; Pajuste K; Sobolev A; Muhamadejev R; Jaudzems K; Duburs G; Kozlovska T Pharmaceuticals (Basel); 2022 Jun; 15(7):. PubMed ID: 35890072 [TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and anti-HBV activity study of novel HBV capsid assembly modulators. Liang M; Liu L; Liu J; Yang Z; Wang M; Xie Y; Cai Y; Xue P; Chen Y; Zhan P; Jia H Bioorg Med Chem Lett; 2024 Nov; 112():129913. PubMed ID: 39111727 [TBL] [Abstract][Full Text] [Related]
12. The Heteroaryldihydropyrimidine Bay 38-7690 Induces Hepatitis B Virus Core Protein Aggregates Associated with Promyelocytic Leukemia Nuclear Bodies in Infected Cells. Huber AD; Wolf JJ; Liu D; Gres AT; Tang J; Boschert KN; Puray-Chavez MN; Pineda DL; Laughlin TG; Coonrod EM; Yang Q; Ji J; Kirby KA; Wang Z; Sarafianos SG mSphere; 2018 Apr; 3(2):. PubMed ID: 29669885 [TBL] [Abstract][Full Text] [Related]
13. Development of benzimidazole-based compounds as novel capsid assembly modulators for the treatment of HBV infection. Du K; Wang X; Bai Y; Zhang X; Xue J; Li S; Xie Y; Sang Z; Tang Y; Wang X Eur J Med Chem; 2024 May; 271():116402. PubMed ID: 38636128 [TBL] [Abstract][Full Text] [Related]
14. Development of a cellular high-content, immunofluorescent HBV core assay to identify novel capsid assembly modulators that induce the formation of aberrant HBV core structures. Sauviller S; Vergauwen K; Jaensch S; Gustin E; Peeters D; Vermeulen P; Wuyts D; Vandyck K; Pauwels F; Berke JM J Virol Methods; 2021 Jul; 293():114150. PubMed ID: 33839187 [TBL] [Abstract][Full Text] [Related]
15. Discovery and antiviral profile of new sulfamoylbenzamide derivatives as HBV capsid assembly modulators. Ivanova Bencheva L; Donnici L; Ferrante L; Prandi A; Sinisi R; De Matteo M; Randazzo P; Conti M; Di Lucia P; Bono E; Giustini L; Vittoria Orsale M; Patsilinakos A; Monteagudo E; Iannacone M; Summa V; Guidotti LG; De Francesco R; Di Fabio R Bioorg Med Chem Lett; 2022 Oct; 73():128904. PubMed ID: 35868496 [TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and evaluation of novel heteroaryldihydropyrimidine derivatives as non-nucleoside hepatitis B virus inhibitors by exploring the solvent-exposed region. Yu J; Jia H; Guo X; Desta S; Zhang S; Zhang J; Ding X; Liang X; Liu X; Zhan P Chem Biol Drug Des; 2020 Jun; 95(6):567-583. PubMed ID: 30825248 [TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and biological evaluation of novel sulfamoylbenzamide derivatives as HBV capsid assembly modulators. Wang S; Ren Y; Li Q; Wang Y; Jiang X; Xu S; Zhang X; Zhao S; Bradley DP; Woodson ME; Zhao F; Wu S; Li Y; Tian Y; Liu X; Tavis JE; Zhan P Bioorg Chem; 2022 Dec; 129():106192. PubMed ID: 36265355 [TBL] [Abstract][Full Text] [Related]
18. Selective depletion of HBV-infected hepatocytes by class A capsid assembly modulators requires high levels of intrahepatic HBV core protein. Kornyeyev D; Song Z; Eng S; Soulette C; Ramirez R; Tang J; Yue Q; Subramanian R; Zaboli S; Moon C; Tam J; Brodbeck J; Aggarwal A; Diehl L; Fletcher SP; Hyrina A; Holdorf MM; Burdette D Antimicrob Agents Chemother; 2024 Jul; 68(7):e0042024. PubMed ID: 38780261 [TBL] [Abstract][Full Text] [Related]
19. Discovery of (1 Wang C; Pei Y; Wang L; Li S; Jiang C; Tan X; Dong Y; Xiang Y; Ma Y; Liu G J Med Chem; 2020 Jun; 63(11):6066-6089. PubMed ID: 32421339 [TBL] [Abstract][Full Text] [Related]
20. Class A capsid assembly modulator apoptotic elimination of hepatocytes with high HBV core antigen level Berke JM; Tan Y; Sauviller S; Wu D-t; Zhang K; Conceição-Neto N; Blázquez Moreno A; Kong D; Kukolj G; Li C; Zhu R; Nájera I; Pauwels F J Virol; 2024 Mar; 98(3):e0150223. PubMed ID: 38315015 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]